nach oben

Acta Diabetologica

Erschienen in:

28.02.2019 | Original Article

Cross-talk between fetal membranes and visceral adipose tissue involves HMGB1–RAGE and VIP–VPAC2 pathways in human gestational diabetes mellitus

Erschienen in: Acta Diabetologica | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims

Gestational diabetes mellitus (GDM) is defined as glucose intolerance that is first diagnosed during pregnancy. Maternal adipose tissue and fetal membranes secrete various molecules that are relevant players in the pathogenesis of GDM. This pilot study aimed to examine whether the expression of the high mobility group box 1 protein (HMGB1) and its receptor for advanced glycation end products (RAGE), and the vasoactive intestinal peptide (VIP) and its receptors (VPAC-1,-2) were modified in pregnant women with GDM.

Methods

Fetal membranes (FMs), omental adipose tissue (VAT) explants, and serum samples were obtained from 12 women with GDM and 12 with normal glucose tolerance (NGT) at delivery. The expression of HMGB1, RAGE and VIP, VPAC-1,-2 was detected by Western Blotting in explants; circulating levels and “in vitro” release of HMGB1 and VIP were measured by ELISA tests.

Results

HMGB1 tissue expression was higher in FMs obtained from GDM women (p = 0.02) than in FMs from NGT women. VPAC2 (p = 0.03) and RAGE (p = 0.03) tissue expressions were significantly increased in VAT from GDM subjects. Only FMs of NGT released detectable levels of HMGB1, which was not observed in samples obtained from GDM. VAT of GDM released lower levels of VIP (p = 0.05) than NGT samples.

Conclusions

This study indicates that a fine tuned regulation exists between FMs and VAT throughout pregnancy to maintain immune metabolic homeostasis. In GDM a balance between inflammatory and anti-inflammatory mediators has been observed. Further studies are needed to establish their exact role on fetal and maternal outcomes in GDM.

Pintaudi B, Fresa R, Dalfra M et al (2018) The risk stratification of adverse neonatal outcomes in women with gestational diabetes (STRONG) study. Acta Diabetol 55(12):1261–1273CrossRefPubMed

Leybovitz-Haleluya N, Wainstock T, Landau D, Sheiner E (2018) Maternal gestational diabetes mellitus and the risk of subsequent pediatric cardiovascular diseases of the offspring: a population-based cohort study with up to 18 years of follow up. Acta Diabetol 55:1037–1042CrossRefPubMed

American Diabetes A (2018) 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S137–S143CrossRef

Bao W, Yeung E, Tobias DK et al (2015) Long-term risk of type 2 diabetes mellitus in relation to BMI and weight change among women with a history of gestational diabetes mellitus: a prospective cohort study. Diabetologia 58(6):1212–1219CrossRefPubMedPubMedCentral

McKenzie-Sampson S, Paradis G, Healy-Profitos J, St-Pierre F, Auger N (2018) Gestational diabetes and risk of cardiovascular disease up to 25 years after pregnancy: a retrospective cohort study. Acta Diabetol 55(4):315–322CrossRefPubMed

Howell KR, Powell TL (2017) Effects of maternal obesity on placental function and fetal development. Reproduction 153(3):R97–R108CrossRefPubMed

Jayabalan N, Nair S, Nuzhat Z et al (2017) Cross talk between adipose tissue and placenta in obese and gestational diabetes mellitus pregnancies via exosomes. Front Endocrinol 8:239CrossRef

Menon R, Richardson LS (2017) Preterm prelabor rupture of the membranes: a disease of the fetal membranes. Semin Perinatol 41(7):409–419CrossRefPubMedPubMedCentral

Pantham P, Aye IL, Powell TL (2015) Inflammation in maternal obesity and gestational diabetes mellitus. Placenta 36(7):709–715CrossRefPubMedPubMedCentral

10.

Skrha J Jr, Kalousova M, Svarcova J et al (2012) Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 120(5):277–281CrossRefPubMed

11.

Giacobbe A, Granese R, Grasso R et al (2016) Association between maternal serum high mobility group box 1 levels and pregnancy complicated by gestational diabetes mellitus. Nutrition, metabolism, and cardiovascular diseases. NMCD 26(5):414–418PubMed

12.

Kang R, Chen R, Zhang Q et al (2014) HMGB1 in health and disease. Mol Asp Med 40:1–116CrossRef

13.

Bredeson S, Papaconstantinou J, Deford JH et al (2014) HMGB1 promotes a p38MAPK associated non-infectious inflammatory response pathway in human fetal membranes. PLoS One 9(12):e113799CrossRefPubMedPubMedCentral

14.

Zhang J, Zhang L, Zhang S et al (2017) HMGB1, an innate alarmin, plays a critical role in chronic inflammation of adipose tissue in obesity. Mol Cell Endocrinol 454:103–111CrossRefPubMed

15.

Monden M, Koyama H, Otsuka Y et al (2013) Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes 62(2):478–489CrossRefPubMedPubMedCentral

16.

Ramhorst R, Calo G, Paparini D et al (2018) Control of the inflammatory response during pregnancy: potential role of VIP as a regulatory peptide. Ann N Y Acad Sci 1437:15–21CrossRefPubMed

17.

Ibrahim H, Barrow P, Foster N (2011) Transcriptional modulation by VIP: a rational target against inflammatory disease. Clin Epigenetics 2(2):213–222CrossRefPubMedPubMedCentral

18.

Giordanetto F, Revell JD, Knerr L et al (2013) Stapled vasoactive intestinal peptide (VIP) derivatives improve VPAC2 agonism and glucose-dependent insulin secretion. ACS Med Chem Lett 4(12):1163–1168CrossRefPubMedPubMedCentral

19.

Forghani P, Petersen CT, Waller EK (2017) Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity. Oncotarget 8(47):81873–81879CrossRefPubMedPubMedCentral

20.

Delgado M, Ganea D (2013) Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids 45(1):25–39CrossRefPubMed

21.

Sekar R, Wang L, Chow BK (2017) Central control of feeding behavior by the secretin, PACAP, and glucagon family of peptides. Front Endocrinol 8:18CrossRef

22.

Associazione Medici Diabetologi (AMD) (2018) Società Italiana di Diabetologia (SID) Standard Italani per la cura del diabete mellito. http://www.standarditaliani.it. Accessed 16 Jan 2019

23.

Scazzocchio B, Vari R, Filesi C et al (2015) Protocatechuic acid activates key components of insulin signaling pathway mimicking insulin activity. Mol Nutr Food Res 59(8):1472–1481CrossRefPubMed

24.

Menon R, Richardson LS, Lappas M (2018) Fetal membrane architecture, aging and inflammation in pregnancy and parturition. Placenta. https://doi.org/10.1016/j.placenta.2018.11.003 CrossRefPubMedPubMedCentral

25.

Baumbusch MA, Buhimschi CS, Oliver EA et al (2016) High Mobility Group-Box 1 (HMGB1) levels are increased in amniotic fluid of women with intra-amniotic inflammation-determined preterm birth, and the source may be the damaged fetal membranes. Cytokine 81:82–87CrossRefPubMedPubMedCentral

26.

Banerjee S, de Freitas A, Friggeri A, Zmijewski JW, Liu G, Abraham E (2011) Intracellular HMGB1 negatively regulates efferocytosis. J Immunol 187(9):4686–4694CrossRefPubMed

27.

Menon R, Bonney EA, Condon J, Mesiano S, Taylor RN (2016) Novel concepts on pregnancy clocks and alarms: redundancy and synergy in human parturition. Hum Reprod Update 22(5):535–560CrossRefPubMedPubMedCentral

28.

Grabowska K, Stapinska-Syniec A, Saletra A, Jarmuzek P, Bomba-Opon D (2017) Labour in women with gestational diabetes mellitus. Ginekologia polska 88(2):81–86CrossRefPubMed

29.

Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM (2014) Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab 25(1):15–22CrossRefPubMed

30.

Alexander KL, Mejia CA, Jordan C et al (2016) Differential receptor for advanced glycation end products expression in preeclamptic, intrauterine growth restricted, and gestational diabetic placentas. Am J Reprod Immunol 75(2):172–180CrossRefPubMed

31.

Wang K, Yang ZQ, Yu HF, Wang YS, Guo B, Yue ZP (2018) High Mobility Group Box 1 regulates uterine decidualization through bone morphogenetic protein 2 and plays a role in Kruppel-Like factor 5-induced stromal differentiation. Cell Physiol Biochem 48(6):2399–2408CrossRefPubMed

32.

Nativel B, Marimoutou M, Thon-Hon VG et al (2013) Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissue. PLoS One 8(9):e76039CrossRefPubMedPubMedCentral

33.

Yamamoto Y, Yamamoto H. RAGE-Mediated Inflammation (2013) Type 2 diabetes, and diabetic vascular complication. Front Endocrinol 4:105CrossRef

34.

Marzioni D, Fiore G, Giordano A et al (2005) Placental expression of substance P and vasoactive intestinal peptide: evidence for a local effect on hormone release. J Clin Endocrinol Metab 90(4):2378–2383CrossRefPubMed

35.

Bajo AM, Juarranz MG, Valenzuela P, Martinez P, Prieto JC, Guijarro LG (2000) Expression of vasoactive intestinal peptide (VIP) receptors in human uterus. Peptides 21(9):1383–1388CrossRefPubMed

36.

Soeters PB, Grimble RF (2013) The conditional role of inflammation in pregnancy and cancer. Clin Nutr 32(3):460–465CrossRefPubMed

37.

Vu JP, Larauche M, Flores M et al (2015) Regulation of appetite, body composition, and metabolic hormones by vasoactive intestinal polypeptide (VIP). J Mol Neurosci 56(2):377–387CrossRefPubMedPubMedCentral

38.

Herrera E, Desoye G (2016) Maternal and fetal lipid metabolism under normal and gestational diabetic conditions. Horm Mol Biol Clin Investig 26(2):109–127PubMed

39.

Akesson L, Ahren B, Edgren G, Degerman E (2005) VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Endocrinology 146(2):744–750CrossRefPubMed

40.

Zhao SJ, Wang DH, Li YW et al (2017) A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects. Int J Nanomed 12:2143–2160CrossRef

Titel: Cross-talk between fetal membranes and visceral adipose tissue involves HMGB1–RAGE and VIP–VPAC2 pathways in human gestational diabetes mellitus
Publikationsdatum: 28.02.2019
Erschienen in: Acta Diabetologica / Ausgabe 6/2019
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-019-01304-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cross-talk between fetal membranes and visceral adipose tissue involves HMGB1–RAGE and VIP–VPAC2 pathways in human gestational diabetes mellitus

Abstract

Aims

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Circulating miRNA-375 levels are increased in autoantibodies-positive first-degree relatives of type 1 diabetes patients

The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies

First case of insulin neuritis after islet transplantation

A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes

A common polymorphism in MIR155 gene promoter region is associated with a lower risk to develop type 2 diabetes

Agonistic autoantibodies against B2-adrenergic receptors correlating with macrovascular disease in longstanding diabetes type 2

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin